Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients ...
ARLINGTON, Va.– According to a new report, complex cells like those in the human body probably resulted from the fusion of genomes from an ancient bacterium and a simpler microbe, Archaea, best known ...
Hosted on MSN
Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced ...
In preclinical studies, a team of researchers from Mount Sinai Health System in New York City and City of Hope in Los Angeles report new findings on a therapeutic combination that regenerated human ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio ...
An "AI scientist," working in collaboration with human scientists, has found that combinations of cheap and safe drugs—used to treat conditions such as high cholesterol and alcohol dependence—could ...
A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...
Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, ...
The SunMo trial was evaluating the novel combination of mosunetuzumab and polatuzumab — not conventional chemotherapy, but a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results